𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status

✍ Scribed by Saul E. Rivkin; William A. Knight; Robert McDivitt; Tony Cruz; Mary Foulkes; C. Kent Osborne; Carol J. Fabian; John J. Costanzi

Publisher
Springer
Year
1985
Tongue
English
Weight
430 KB
Volume
9
Category
Article
ISSN
0364-2313

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Is it time to develop an optimal endocri
Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?
✍ Malcolm M. Bilimoria; V. Craig Jordan πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 655 KB

One hundred years ago ovarian ablation was shown to be an effective treatment for advanced breast cancer in premenopausal women. Since that time many different treatment modalities have been advocated to improve patient survival. The value of adjuvant ovarian ablation, however, has recently been est

Benefit and projected cost-effectiveness
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer
✍ Bruce E. Hillner πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 125 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (β€˜Arimidex, Tamoxifen Alone or in Combinatio